KI-Beratung Beta

Produktbild: Lipoprotein(a)
- 13%

Lipoprotein(a)

Aus der Reihe Contemporary Cardiology
13% sparen

203,99 € UVP 235,39 €

inkl. gesetzl. MwSt., Versandkostenfrei


Beschreibung

Lipoprotein(a) [Lp(a)] is a unique lipoprotein that has emerged as an independent risk factor for cardiovascular vascular disease.  Data from case control, epigenetic and mendelian randomization studies indicate that people with elevated Lp(a) have a two-fold to four-fold increased risk of cardiovascular...

Beschreibung

Lipoprotein(a) [Lp(a)] is a unique lipoprotein that has emerged as an independent risk factor for cardiovascular vascular disease.  Data from case control, epigenetic and mendelian randomization studies indicate that people with elevated Lp(a) have a two-fold to four-fold increased risk of cardiovascular events compared to people with low Lp(a) levels. Despite this risk, awareness of Lp(a) is still very low among health care providers. Even cardiologists often overlook Lp(a), in part because Lp(a) is not as well-understood as other risk factors and treatment options are still very limited. 

 

This book offers an authoritative and comprehensive overview of Lipoprotein(a). It provides an in-depth review of all aspects of Lp(a), from pathophysiology to metabolism. Chapters offer the reader a contemporary view of the important roles of Lp(a) as a risk factor for cardiovascular disease. In addition, this volume discusses the clinical implications of elevated Lp(a) and current and future therapies. 

 

Lipoprotein(a)
 is an essential resource for physicians, medical students, residents, fellows, and allied health professionals in lipidology, cardiology, endocrinology, pharmacotherapy, and health promotion and disease prevention.

Portrait


Karam Kostner, MD, Ph.D., FRACP,  FCSANZ

Associate Professor of Medicine

University of Queensland and Mater Hospital

Brisbane, Australia


Gerhard M. Kostner, Ph.D.

Emeritus Professor of Biochemistry and Molecular Biology

Medical University of Graz, Austria

Graz, Austria


Peter P. Toth, M.D. , PhD, FAHA, FESC, FACC

Adjunct Professor of Medicine

Division of Cardiology

Johns Hopkins University School of Medicine

Baltimore, Maryland  USA

Produktdetails

Einband

Gebundene Ausgabe

Erscheinungsdatum

04.03.2023

Abbildungen

XVII, 443 p. 92 illus., 76 illus. in color.

Herausgeber Karam Kostner + weitere

Produktdetails

Einband

Gebundene Ausgabe

Erscheinungsdatum

04.03.2023

Abbildungen

XVII, 443 p. 92 illus., 76 illus. in color.

Herausgeber
Verlag Springer
Seitenzahl

443

Maße (L/B/H)

24,1/16/2,9 cm

Gewicht

890 g

Auflage

2023

Sprache

Englisch

ISBN

978-3-031-24574-9

Herstelleradresse

Springer-Verlag GmbH
Europaplatz 3
69115 Heidelberg
DE

Email: ProductSafety@springernature.com

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)

  • Produktbild: Lipoprotein(a)

  • 60 years of Lp(a) research-From Ouchterlonys double diffusion to a significant risk factor for CHD.- Lp(a) structure and composition.- Genetics of Lipoprotein(a).- Lp(a) metabolism.- Contemporary aspects of Lp(a) metabolism and therapies based on tracer kinetic methods.- Role of Proprotein Convertase Subtilisin Kexin type 9 in Lipoprotein(a) Metabolism.- The Role of Cell Surface Receptors in Lp(a) Metabolism.- Physiological Roles And Functions Of Lipoprotein(a).- The role of Lp(a) in Atherosclerosis: An overview.- Role of macrophages in Lp(a) pathophysiology.- Thrombosis, Inflammation and Lipoprotein(a): Clinical Implications .- The role of the kidney in Lp(a) physiology and pathophysiology.- Lp(a) as a cardiovascular risk factor.- Lp(a) and aortic valve stenosis, stroke, and other non-coronary cardiovascular diseases.- Lp(a) in cardiovascular disease: Evidence from Large Epidemiological Studies.- Lipoprotein(A) And Immunity.- When to measure Lp(a) .- Measurement of Lipoprotein (a) in the Clinical Laboratory.- Standardization of analytical methods for the measurement of Lipoprotein(a): bridging  past and future initiatives.- Establishing an SI-traceable Reference Measurement System for Lp(a), based on Quantitative Protein Mass Spectrometry and Molar Units.- Compounds that impact Lp(a) concentrations.- Antisense oligonucleotide therapy to treat elevated lipoprotein(a).- Lipoprotein apheresis for reduction of Lipoprotein(a).- Elevated Lp(a) - Why Should I Test For It, If I Cannot Treat It? A Patient’s Perspective .- Burning unanswered questions Therapy.